TCRX · TScan Therapeutics, Inc.
$0.32
+0.00 (+0.79%)
At close · Sep 11
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, substantial doubt about the Company's ability to continue as a going concern exists. ... These conditions raise substantial doubt about the Company's ability to continue as a going concern. ... Therefore, substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”View the 10-Q filed Aug 12, 2026
Market Cap
$21.72M
Shares
67.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.32
Open$0.32
Day$0.31–0.33
52W close$0.32–2.52
Avg vol 30d830K
Short int1.7M · 2.6% float · 7.0d
Short vol48%
Last earningsMay 6, 2025
DataJul 2021–Sep 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$7.11M
Trailing 12 months
Net income (TTM)
−$117.71M
Trailing 12 months
Revenue growth YoY
-65.8%
Year over year
Operating margin
-1,695.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-545.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.2%
Year over year · more shares
Price change (1Y)
-82.7%
Trailing year
Short interest
2.6%
Latest settlement · 7.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−68%
below
Price vs 50-day avg
−59%
below
RSI (14)
18
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−59%
trailing
6-month return
−69%
trailing
YTD return
−68%
this year
Relative strength
−87%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.58% of float · ▲ +9.3% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
60 holders — mid 3-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+267%
Y/Y
EPS growth
+12%
Y/Y
Free cash flow
$-139.7M
Balance sheet
$119.9M
net cash
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
18.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−68%
Bearish
Price vs 50-day avg
−59%
Bearish
RSI (14)
18
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.58% of float · ▲ +9.3% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
60 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $3
vs 200-day avg -68%
vs 50-day avg -59%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TCRX
this stock
TScan Therapeutics, Inc.
|
$21.72M | -68.0% | +266.7% | — | 2.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TCRX | -13.6% | -58.5% | -69.2% | -56.1% | -68.0% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -12.5% | -56.8% | -87.0% | -55.7% | -80.0% |
Key facts
CIK
1783328
CUSIP
89854M101
13F (30d)
26 filings
26 filers
Visit website
Investor relations